Investor Briefing with James McDonnell
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
One in five people will get cancer in their lifetime – almost everyone has been...
Prescient is focused on developing new therapies for cancers with unmet needs.

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.